Pfizer's arthritis drug shows efficacy in late-stage trial

06/20/2010 | Reuters

Patients with rheumatoid arthritis demonstrated significant reduction in knee pain and improvement in physical function after receiving one of three doses of Pfizer's injectable biotech drug tanezumab during a late-stage trial. The medicine targets nerve growth factor, a protein associated with pain.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ